A V530I mutation in c-KIT exon 10 is associated to imatinib response in extraabdominal aggressive fibromatosis

Sarcoma

Volumn 2010, Issue , 2010, Pages

  Kurtz, Jean Emmanuel ^a   Asmane, Irne ^a   Voegeli, Anne Claire ^a   Neuville, Agns ^a   Dufresne, Armelle ^b   Litique, Valre ^a   Chevreau, Christine ^c   Bergerat, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CORE BINDING FACTOR; IMATINIB; STEM CELL FACTOR;

ABDOMINAL FIBROMATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DESMOID TUMOR; EXON; EXTRAABDOMINAL AGGRESSIVE FIBROMATOSIS; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MASTOCYTOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SHOULDER PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77951610707     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2010/458156     Document Type: Article

References (22)

1. Alman B. A., Pajerski M. E., Diaz-Cano S., Corboy K., Wolfe H. J., Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder Diagnostic Molecular Pathology 1997 6 2 98 101 (Pubitemid 27155030)
2. Stoeckle E., Coindre J. M., Longy M., A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases European Journal of Surgical Oncology 2009 35 2 129 134
3. Duffaud F., Le Cesne A., Imatinib in the treatment of solid tumours Targeted Oncology 2009 4 1 45 56
4. Corless C. L., McGreevey L., Town A., KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors Journal of Molecular Diagnostics 2004 6 4 366 370 (Pubitemid 39517405)
5. Mace J., Sybil Biermann J., Sondak V., Response of extraabdominal desmoid tumors to therapy with imatinib mesylate Cancer 2002 95 11 2373 2379 (Pubitemid 35351145)
6. Gonalves A., Monges G., Yang Y., Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis Journal of the National Cancer Institute 2006 98 8 562 563 (Pubitemid 43898822)
7. Wcislo G., Szarlej-Wcislo K., Szczylik C., Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature Journal of Cancer Research and Clinical Oncology 2007 133 8 533 538 (Pubitemid 46955681)
8. Heinrich M. C., McArthur G. A., Demetri G. D., Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor) Journal of Clinical Oncology 2006 24 7 1195 1203 (Pubitemid 46638818)
9. Fayette J., Dufresne A., Penel N., Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma Group-GETO study Journal of Clinical Oncology 2007 25 18, supplement. abstract no. 10062
10. Seinfeld J., Kleinschmidt-Demasters B. K., Tayal S., Lillehei K. O., Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status Journal of Neurosurgery 2006 104 5 749 756
11. Tamborini E., Negri T., Miselli F., Lagonigro M. S., Pricl S., Pilotti S., Re: response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis Journal of the National Cancer Institute 2006 98 21 1583 1584 (Pubitemid 44680910)
12. Bertucci F., Gonalves A., Viens P., Monges G., Dubreuil P., Desmoid-type fibromatosis Journal of Neurosurgery 2007 107 2 473 475; author reply 475
13. Krger S., Emig M., Lohse P., Ehninger G., Hochhaus A., Schackert H. K., The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians Leukemia 2006 20 2 354 355 (Pubitemid 43148677)
14. Yin X.-Y., Ren Y.-Q., Yang S., A novel KIT missense mutation in one Chinese family with piebaldism Archives of Dermatological Research 2009 301 5 387 389
15. Orfao A., Garcia-Montero A. C., Sanchez L., Escribano L., Recent advances in the understanding of mastocytosis: the role of KIT mutations British Journal of Haematology 2007 138 1 12 30 (Pubitemid 46889785)
16. Cammenga J., Horn S., Bergholz U., Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate Blood 2005 106 12 3958 3961 (Pubitemid 41739038)
17. Gari M., Goodeve A., Wilson G., c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia British Journal of Haematology 1999 105 4 894 900 (Pubitemid 29309094)
18. Boissel N., Leroy H., Brethon B., Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) Leukemia 2006 20 6 965 970 (Pubitemid 43797286)
19. Cairoli R., Beghini A., Morello E., Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations: a report of three cases Leukemia Research 2005 29 4 397 400 (Pubitemid 40255813)
20. Cortes J., Giles F., OBrien S., Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders Cancer 2003 97 11 2760 2766 (Pubitemid 36605143)
21. Growney J. D., Clark J. J., Adelsperger J., Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 Blood 2005 106 2 721 724 (Pubitemid 40981272)
22. Skubitz K. M., Manivel J. C., Clohisy D. R., Frolich J. W., Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors Cancer Chemotherapy and Pharmacology 2009 64 3 635 640